News and Milestones

  • 2020 Q4
    – Darmiyan presented validation results in CTAD 2020
  • 2020 Q2 & Q3
    – Darmiyan CEO was selected by Fortune 40 under 40
    – Darmiyan’s core technology, BrainSee, was blind-tested and validated by independent third-party investigators in the US and Canada. See press release here.
  • 2020 Q1
    – Pharma giant Eisai led a $6M round in Darmiyan
    – US patent was published
  • 2019 Q4
    – Blind testing validation results are published in BioRxiv, and established ~ 90% accuracy in the diagnosis of MCI and AD and 5-year prognosis of MCI
    – Started POC study with Banner Alzheimer’s Institute, focused on early detection of AD at preclinical (presymptomatic) stage
    – Presented at CTAD (Clinical Trials on Alzheimer’s Disease) 2019 conference, San Diego
    – Presented at Washington Longevity Summit, Washington DC
    – Press room in Washington DC
  • 2019 Q3
    – Released BrainSee version 1.0 
    – Tested the product on 3170 brain scans (Normal, MCI, AD) and 411 longitudinal MCI cases with 5-year follow up
    – Signed partnership with Mary Furlong & Associates
    – Podcast with Dr. Allison Sekuler, Mary Furlong and Darmiyan CTO Dr. Kaveh Vejdani  recorded in UC Berkeley 
    – Patents filed in Europe and Asia
  • 2019 Q2
    – Developed a fully automated pipeline for image processing and data analysis
    – Featured article, Alzheimer’s disease noise or signal, in response to Bill Gates
  • 2019 Q1
    – Met with FDA in Washington to discuss regulatory strategy 
    – Partnership signed with CABHI (Center for Aging and Brain Health Innovation) partner sites Baycrest Institute, University Health Network (UHN) and Hamilton Health Sciences
    – Presented at CABHI’s What’s Next Canada meeting in Toronto and won the 2019 CABHI Innovation Award 
    – Toronto office was opened to explore business development opportunities in Canada
  • 2018 Q4
    – Presented at TEDMED Hive, Palm Springs, CA
    – FDA Q-sub (pre-submission) application sent
  • 2018 Q3
    – Panelist at MedTech Conference, Neurotechnology section, Philadelphia, PA
    – Moved to a new office space in downtown San Francisco, CA
  • 2018 Q2
    – Won a CABHI Industry Innovation (I2P2) award for CAN $500K
    – PCT patents filed and US patent application was fast-tracked
    – Signed partnership agreement with Boston University
  • 2018 Q1
    – Image analysis and machine learning pipelines designed and developed 
    – Signed partnership agreement with Banner Alzheimer’s Institute
  • 2017 Q4
    – Graduated from SkyDeck UC Berkeley 
    – Moved to new office space in Emeryville, CA, team expanded to 6 FTE
    – Non-provisional US patent filed
  • 2017 Q3
    – Graduated from Y-Combinator program 
    – Raised seed financing
    – VentureBeat news published 
    – Hacker News article released 
    – WSGR engaged as IP legal counsel
  • 2017 Q2
    – Won Amgen-QB3/MBC Biolabs Golden Ticket Award
    – Accepted to Y-Combinator S17 Batch
    – Accepted to SkyDeck UC Berkeley
  • 2017 Q1
    – Product designed and strategy identified  
    – Prototype developed and got preliminary results
  • 2016
    – Paul Hastings LLP engaged as legal counsel
    – Incorporated in Delaware
    – Registered in California and raised pre-seed financing
  • 2015
    – Completed the feasibility studies and model validation by microscopy
    – Member company of Harlem Biospace, New York
  • 2014
    – Developed the core technology and product concept
    – Successfully completed New York regional NSF I-Corps program